Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib cardiac safety study in healthy volunteers
NCT03432884Phase 1Completed
- Sponsor
- BeiGene
- Start
- Jan 2018
- Primary completion
- Apr 2018
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of zanubrutinib in mantle cell lymphoma (MCL), Waldenstrom macroglobulinemia (WM), chronic lymphocytic leukemia (CLL) and 3 more (3 arms), sponsored by BeiGene. Primary endpoints: Incidence of treatment-emergent adverse events (safety and tolerability) up to 8 days and Corrected QT interval [QTc] up to 2 days. Started Jan 2018; status: completed.
02
Drugs
zanubrutinib
03
Conditions
mantle cell lymphoma (MCL)Waldenstrom macroglobulinemia (WM)chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)marginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT03432884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03432884.